| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442635 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
Continuous daily oral S-222611 is well tolerated, modulates oncogenic signalling, and has significant antitumour activity. The recommended Phase 2 dose, based on PK and efficacy, is 800Â mg/day.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
J. Spicer, R. Baird, A. Suder, N. Cresti, J. Garcia Corbacho, L. Hogarth, E. Frenkel, S. Matsumoto, I. Kawabata, K. Donaldson, J. Posner, D. Sarker, D. Jodrell, R. Plummer,